Artelo Biosciences (NASDAQ:ARTL) Issues Quarterly Earnings Results, Misses Expectations By $3.22 EPS

Artelo Biosciences (NASDAQ:ARTL) announced its quarterly earnings results on Thursday. The company reported ($4.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($3.22), FiscalAI reports.

Artelo Biosciences Price Performance

Shares of NASDAQ ARTL opened at $2.34 on Friday. The business has a 50-day moving average of $4.92 and a 200-day moving average of $5.05. The stock has a market capitalization of $2.20 million, a price-to-earnings ratio of -0.04 and a beta of 0.05. Artelo Biosciences has a fifty-two week low of $2.30 and a fifty-two week high of $85.80.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ARTL shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Friday, March 27th. Wall Street Zen cut Artelo Biosciences to a “strong sell” rating in a research report on Saturday, April 25th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $54.00.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.